IndraLab

Statements


1 | 4 1 8

eidos
"Consistent with this view , global knockout of the cGAS-cGAMP-STING downstream target TBK1 ( 37 ) or IRF3 ( 38 ) , or pharmacological inhibition of IkappaB kinase epsilon ( IKKepsilon ) and TBK1 by amlexanox , reduced body weight , enhanced insulin sensitivity , and improved glucose tolerance in obese mice and in a subset of patients with type 2 diabetes ( 34,39 ) ."

eidos
"Collectively , we found that inhibition of the TBK1 and IKKepsilon by amlexanox is a promising therapeutic strategy to cure liver fibrosis ."

eidos
"Based on histopathologic analysis using H & E and Sirius-red staining , inhibition of TBK1 and IKKepsilon by amlexanox markedly reduced biliary hyperplasia and collagen deposition in the livers of mice fed with DDC diet ( Figure 2B , C ) ."

reach
"Amlexanox blocks activity of TBK1 and IKKepsilon with a half maximal inhibitory concentration (IC50) of approximately 1-2 muM."

reach
"Amlexanox is a specific inhibitor of IKKepsilon and TBK1."

reach
"Amlexanox, which is known to inhibit TBK1 and IKKepsilon selectively, is an approved drug for the treatment of bronchial asthma, allergic rhinitis, and conjunctivitis in Japan and elsewhere."

No evidence text available

reach
"14 We found that amlexanox treatment could inhibit the IKBKE protein and alter the abundance and phosphorylation status of the Hippo pathway proteins in glioma cells."

reach
"Recently, amlexanox has been shown to inhibit TBK1 and IKKepsilon, both of which are induced in the liver and fat by high-fat diet mediated NF-kappaB activation [XREF_BIBR]."

eidos
"As more effective therapeutic strategies are urgently needed for treating hepatic fibrosis and cirrhosis , inhibition of TBK1 and IKKepsilon by amlexanox may be a promising therapeutic strategy to cure fibrosis , which could allow for remodelling and regression of fibrosis ."

reach
"Amlexanox Amlexanox is an inhibitor of noncanonical IkappaB kinases IKK-epsilon and TANK binding kinase 1."

reach
"Recently, Reilly et al. [XREF_BIBR] discovered a small molecule inhibitor of IKKepsilon and TBK1 kinases called amlexanox, which has been shown to selectively inhibit both IKKepsilon and TBK1."

reach
"Blocking TBK1 and IKKepsilon during transduction of NK cells enabled their efficient transduction by VSV-G LVs as judged by YFPexpression of 40-50%, with half maximal effective concentrations of 1.1 microM (MRT67307), 5 microM (BX-795) and 24.8 microM (amlexanox)."

trips
"Amlexanox Enhances Temozolomide-Induced Antitumor Effects in Human Glioblastoma Cells by Inhibiting IKBKE and the Akt-mTOR Signaling Pathway."